Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...
As the race to harness CAR-T cells for autoimmune diseases hits a rough patch, a Bay Area biotech is gliding over the ...
Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform ...
Roche’s Genentech is paying Earendil Labs $55 million upfront to discover and develop multiple bispecific antibodies. The ...
Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up ...
Overton conceded multiple times during the hearing that vaccines approved by the FDA, as well as the so-called “abortion pill ...
Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug ...
Telix paid $165 billion upfront primarily to secure ITM’s lead radioligand candidate ITM-11, which was recently rejected by ...
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
As two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an ...
Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover ...
Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike ...
Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug that the Big Pharma bought in a $3 billion takeover.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results